Pusat Pengajian Sains Farmasi - Tesis

Browse

Now showing 1 - 5 of 694

Development, Optimization And Characterization Of Cisplatin Loaded Cubosomes For Human Lung Carcinoma
(2025-06)
Hassaan, Umar
Lung cancer remains a major global health challenge due to the limitations of conventional therapies. Platinum-based chemotherapy, such as cisplatin, is widely used but hindered by systemic toxicity and rapid clearance. To address these issues, we developed a novel glyceryl monooleate (GMO)-based cubosomes platform for sustained cisplatin delivery, leveraging its unique bicontinuous lipid structure to overcome encapsulation and release limitations of existing nanocarriers like liposomes and polymeric nanoparticles.
Impact Of Blood Glucose Trajectories On Pathological Responses, Severity And Quality Of Life Associated With Cipn In Breast Cancer Women After Receiving Neo Adjuvant Chemotherapy: A Single Center Study In Pakistan
(2025-06)
Javed, Saba
Breast cancer is a significant health concern in developed and underdeveloped countries. A dual-phase study (Retrospective and Prospective) was performed at the Gujranwala Institute of Nuclear Medicine and Radiotherapy (GINUM), Gujranwala, Pakistan. The retrospective phase, which involved the extraction of data from the medical records of 1,372 women with breast cancer between January 2016 and January 2021, successfully accomplished the first objective of the project. This study phase revealed significant differences in pathological responses to treatment between diabetic and non-diabetic breast cancer patients (p<0.001). Diabetic patients exhibited a lower rate of pathological complete response (15.7%) compared to (19.9%) non-diabetic patients.
Evaluation Of Knowledge And Practices On Pharmacotherapy, Drug-Related Problems, Antiemetic Consistency, And Impact On Quality Of Life In Non-Hodgkin'S Lymphoma Care In Yemen
(2025-03)
Battah, Mohammed Mohammed Rezq
Non-hodgkin lymphoma (nhl) is a heterogeneous group of cancers with increasing incidence globally. Optimal pharmacotherapy management is crucial for improving treatment outcomes and patient quality of life (hrqol). However, in resource-limited settings like yemen, the quality of nhl care may be suboptimal due to various challenges, including limited access to resources, inadequate training, and lack of standardised treatment guidelines. This study aimed to comprehensively evaluated nhl pharmacotherapy in yemen, focusing on healthcare provider knowledge and practices, antiemetic guideline adherence, drps, and patients' hrqol. Conducted from january 2022 to september 2023, the study included cross-sectional surveys of physicians and nurses from eight oncology centers and units and 300 adult nhl patients at the national oncology center (noc) in sana'a. Data collection involved validated questionnaires, face-to-face interviews, medical records, treatment charts, and the fact-lym questionnaire. Among 77 physicians and 105 nurses, 54.3% of nurses and 66.2% of physicians had poor knowledge of nhl pharmacotherapy, with 83.8% of nurses and 75.3% of physicians showing poor practice. Chemotherapy knowledge and practice improved with adequate information and specialized training. Only 23.9% of 251 nhl patients received antiemetic treatment consistent with nccn guidelines.
The Association Of Cyp3a4, Cyp3a5 And Mthfr Genes Polymorphism On The Efficacy And Safety Of Atorvastatin Among Egyptian Population
(2025-03)
Maslub, Mohammed Gamal Mohammed
Dyslipidemia raises cardiovascular diseases (cvds) risk in egyptians. Tailoring atorvastatin treatment based on genotype can enhance efficacy and reduce adverse effects, contributing to the egyptian genome project’s efforts to improve health outcomes. Previous studies have not provided conclusive evidence regarding the association between response to atorvastatin and cyp3a4 and cyp3a5 genetic polymorphisms. Further research is necessary to confirm the mthfr gene variation as a predictive biomarker for responsiveness to atorvastatin. The effects of genetic polymorphisms on atorvastatin therapy were not previously studied among the egyptians. This research aimed to investigate the effects of cyp3a4*1b (rs2740574 c/t), cyp3a4*22 (rs35599367 g/a), cyp3a5*3 (rs776746 t/c), and mthfr (rs1801133 g/a) polymorphisms on atorvastatin treatment in egyptians. In this prospective cohort study, 100 subjects were genotyped for these alleles. All participants were screened for serum lipid profiles, liver enzymes, total bilirubin (tb), and creatine kinase (ck) before and after a four-week therapy with 40 mg of atorvastatin.
Development Of Multi-Criteria Decision Analysis (Mcda) Framework For Formulary Listing Decisions Of Oncology Drugs In Malaysia
(2025-04)
Chandriah, Haarathi
Given the increasing incidence of cancer in the country and the introduction of new high-cost innovative medicines, ensuring access to cancer drugs remains a significant public health challenge. National formulary listing and drug pricing play crucial roles in ensuring access to these drugs. The current issues surrounding cancer drug prices and access in the country are not known. Moreover, the existing health technology assessment (hta) approach for value assessment of cancer drugs for formulary listing is considered to be lacking in comprehensiveness as it does not fully capture other dimensions of value such as disease severity. Therefore, this thesis aims to develop a multi criteria decision analysis (mcda) framework for value assessment of cancer drugs while concurrently investigating other issues related to access to cancer drugs. Documents review and secondary data analysis using formulary listing data from year 2011 to 2018 was conducted to identify challenges related to cancer drug access. In developing the mcda framework, a cross-sectional survey involving multiple stakeholders was conducted to determine preferences for formulary decision criteria.

Browse

Recent Submissions